AK Pharma

Denosumab 60 mg vs 120 mg: What the Prolia and Xgeva Labels and Trials Report

Denosumab 60 mg vs 120 mg is a comparison hospital pharmacies run into often, because the same medicine is stocked in two very different forms under two different brand names. The 60 mg product (sold as Prolia) and the 120 mg product (sold as Xgeva) contain the same antibody, yet thei

Neutropenia and G-CSF Therapy in India: What Labels and Guidelines Report

Granulocyte colony-stimulating factors (G-CSFs) such as filgrastim are used in oncology to address neutropenia, a low neutrophil count that raises the risk of serious infection during chemotherapy. Several items bear on how they are discussed: the American Society of Clinical Oncology

Epinephrine Auto-Injectors in India: What the EpiPen Label and Anaphylaxis Guidance Report

Epinephrine (adrenaline) auto-injectors such as EpiPen and EpiPen Jr are single-dose, pre-filled devices that deliver a fixed dose of epinephrine into the outer thigh. Several recent items bear on how they are discussed: the US prescribing information for EpiPen and EpiPen Jr was revi

India’s First Alzheimer’s Disease-Modifying Therapy Is Now Available — What It Means for Patients and Hospitals

For decades, treating Alzheimer’s disease in India meant managing symptoms. Medications like rivastigmine and donepezil could slow cognitive decline for a period, but nothing available in the Indian market could actually target the disease process itself — the accumulating amyloid

Named Patient Program vs Patient Assistance Program — What Indian Consumers Need to Know

Two programs. Two very different purposes. And yet, for patients and families navigating serious illness in India, the terms Named Patient Program and Patient Assistance Program come up in the same conversations, recommended by the same doctors, and processed through the same hospital

Named Patient Program vs Patient Assistance Program — What Indian Consumers Need to Know

Two programs. Two very different purposes. And yet, for patients and families navigating serious illness in India, the terms Named Patient Program and Patient Assistance Program come up in the same conversations, recommended by the same doctors, and processed through the same hospital